aceAI identifies tumor aging patterns to predict immunotherapy response across multiple cancer types
Even when given the same drug, some patients respond well while others show little or no response. This is particularly true of immunotherapy. A research team at POSTECH (Pohang University of Science and Technology) has developed an artificial intelligence (AI) technology that can predict, in advance, which patients are likely to benefit from treatment.
An AI tool developed at POSTECH aims to identify before treatment which patients are likely to benefit from immunotherapy, which could help address uneven patient responses to the same drug.
Evidence
- JournalismMedical Xpress2026-10-21
How should this claim be treated?
Truvace Impact Record TRV-2026-2152, v1: “AI identifies tumor aging patterns to predict immunotherapy response across multiple cancer types.” Truvace, 2026-10-22. /record/TRV-2026-2152 (accessed at citation time). sha256 2a2f40832d16aa9a…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-2152 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.